TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10544396

Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 117

Group type: COMPARATOR
Intervention: Lidocaine 2%
Number of subjects: 117
Study: 8508193

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) condition with increased carbohydrate intake from 5.8 to 8.8 g kg‐1 BW, supplemented with a 16.5% glucose polymer solution.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (C) group with an isocaloric diet, additional energy from fat and protein.
Number of subjects: 16
Study: 3691011

Group type: EXPERIMENTAL
Intervention: Unflavored oral suspension (20 mg/mL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tablets (two 200-mg tablets)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flavored and unflavored carbamazepine suspensions
Number of subjects: 12
Study: 30557965

Group type: EXPERIMENTAL
Intervention: Low-dose MDCT (ldMDCT)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard-dose MDCT (sdMDCT)
Number of subjects: 288
Study: 27420732

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) with a 940 nm diode laser, energy of 4 J/cm² applied to one side immediately after surgery
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (no laser energy applied)
Number of subjects: 35
Study: 25142813

Group type: EXPERIMENTAL
Intervention: Edaravone (intravenous 30 mg twice per day for 2 weeks)
Number of subjects: 137
Study: 22692521

Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking (CXL)
Number of subjects: 76
Study: 20651094

Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional dentifrice
Number of subjects: 0
Study: 17873681

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus rivastigmine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Rivastigmine alone
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Rivastigmine plus fluoxetine
Number of subjects: 122
Study: 16149837

Group type: EXPERIMENTAL
Intervention: Digital photographic technique for measuring head shapes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flexicurve ruler for measuring head shapes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oblique cranial length ratio
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cephalic index
Number of subjects: 60
Study: 12131309

Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block
Number of subjects: 100

Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 100
Study: 10520836

Group type: EXPERIMENTAL
Intervention: i.v. pantoprazole (20, 40, 80, or 120 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: i.v. pantoprazole (80 and 120 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: i.v. famotidine (20 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 39
Study: 8730940

Group type: EXPERIMENTAL
Intervention: Public education campaign (didactic component)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no educational campaign)
Number of subjects: 0
Study: 1757751

Group type: EXPERIMENTAL
Intervention: PlanAlyzer interactive program for anemia diagnosis
Number of subjects: 328

Group type: COMPARATOR
Intervention: Traditional textual materials for anemia diagnosis
Number of subjects: 328
Study: 7064850

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Acebutolol (100 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined nifedipine and acebutolol
Number of subjects: 21
Study: 31756383

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral pain management intervention (WebMAP)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Web-based pain education program (WebED)
Number of subjects: 260
Study: 30624952

Group type: EXPERIMENTAL
Intervention: Sardinian folk dance (Ballu Sardu, BS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 28807845

Group type: EXPERIMENTAL
Intervention: Real 1-Hz rTMS (2000 stimuli, 110% motor threshold)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Real 1-Hz rTMS
Number of subjects: 163

Group type: COMPARATOR
Intervention: Real 1-Hz rTMS and Sham rTMS
Number of subjects: 163
Study: 25504267

Group type: EXPERIMENTAL
Intervention: Quadripolar lead
Number of subjects: 418

Group type: COMPARATOR
Intervention: Bipolar lead
Number of subjects: 418
Study: 23085503

Group type: EXPERIMENTAL
Intervention: Sertraline (initial dose of 50mg once daily, with dose escalation to a maximum of 200mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (matching placebo to sertraline)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200
Study: 21821474

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 400

Group type: COMPARATOR
Intervention: Population-based control group
Number of subjects: 400
Study: 19196887

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 69

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 69
Study: 17468863

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg, twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg, twice daily plus esomeprazole 40 mg, once daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg, once daily
Number of subjects: 90
Study: 14735174

Group type: EXPERIMENTAL
Intervention: Oral topotecan
Number of subjects: 190

Group type: COMPARATOR
Intervention: Infusion topotecan
Number of subjects: 190
Study: 11504276

Group type: COMPARATOR
Intervention: FFR‐rFVIIa (0.01, 0.02, 0.05, 0.08, 0.12, 0.18, 0.27, or 0.40 mg/kg body weight)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 9737352

Group type: EXPERIMENTAL
Intervention: Menatetrenone (MK-4) 45 mg daily for 12 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 108
Study: 9495218

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) treatment
Number of subjects: 85
Study: 1983508

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) Fragmin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Unfractionated heparin Calciparin
Number of subjects: 90
Study: 304126

Group type: EXPERIMENTAL
Intervention: Surgery (332 patients)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Medical treatment (354 patients)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Surgery (in patients with left main disease)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Surgery (in patients with triple vessel disease)
Number of subjects: 686
Study: 31896431

Group type: EXPERIMENTAL
Intervention: Grocery shopping skill program (8 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional rehabilitation (wait-list group)
Number of subjects: 20
Study: 31842969

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM), 10 g/packet, twice daily for 2 weeks
Number of subjects: 378

Group type: COMPARATOR
Intervention: CM placebo, 10 g/packet, twice daily for 2 weeks
Number of subjects: 378
Study: 28288296

Group type: EXPERIMENTAL
Intervention: ProNamel®
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tooth Mousse™
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 25521535

Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 300

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 300
Study: 23871490

Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab
Number of subjects: 5102

Group type: EXPERIMENTAL
Intervention: 2 years of trastuzumab
Number of subjects: 5102

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 5102
Study: 21792500

Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cemented total hip arthroplasty
Number of subjects: 250
Study: 19234715

Group type: EXPERIMENTAL
Intervention: Standing arm-cranking (grinding)
Number of subjects: 33
Study: 17921553

Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dexamethasone + Glycerol
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 15264186

Group type: EXPERIMENTAL
Intervention: HD with HF80(S)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HD with FX80
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: postdilution HDF, 20 L, with FX80
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: predilution HDF, 20 L, with FX80
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: predilution HDF, 60 L, with FX80
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HDF
Number of subjects: 14

Group type: COMPARATOR
Intervention: High‐flux HD
Number of subjects: 14
Study: 11578788

Group type: EXPERIMENTAL
Intervention: Atorvastatin plus vitamin C and vitamin E
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1007
Study: 9745160

Group type: EXPERIMENTAL
Intervention: Group A: DeNol 120 mg, amoxicillin 500 mg and metronidazole 250 mg four times a day orally for 14 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group B: omeprazole 20 mg plus clarithromycin 500 mg twice a day and amoxicillin 500 mg four times a day for 14 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group C: omeprazole 20 mg, clarithromycin 250 mg and metronidazole 500 mg twice a day for seven days
Number of subjects: 90
Study: 7990079

Group type: EXPERIMENTAL
Intervention: Angiotensin II (5 ng/kg/min) infusion for three hours
Number of subjects: 5

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 5
Study: 3198000

Group type: EXPERIMENTAL
Intervention: ICS 205-930, 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: ICS 205-930, 10 mg
Number of subjects: 12
Study: 31877381

Group type: EXPERIMENTAL
Intervention: Cyst-like component of subchondral BMLs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Synovial tissue volume (STV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Total subchondral BML volume
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Total ligament-based BML volume
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subchondral BMLs with cyst-like component
Number of subjects: 50
Study: 30213849

Group type: EXPERIMENTAL
Intervention: 89Zr-deferoxamine-ZEGFR:03115 (2.4-3.6 MBq, 2 μg) co-injected with 10 μg of nonlabeled ZEGFR:03115
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 18F-aluminium fluoride-NOTA-ZEGFR:03115 (12 μg, 1.5-2 MBq/mouse)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PET imaging data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PET analysis
Number of subjects: 0
Study: 29285569

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25319131

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment (US) at 1 MHz, intensity of 1.5 W/cm², continuous mode, applied five times a week for 2 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 0.8 J/cm² with 905 nm wavelength, applied five times a week for 2 weeks
Number of subjects: 32
Study: 23294481

Group type: EXPERIMENTAL
Intervention: Parental education regarding changing to reduced-fat dairy foods
Number of subjects: 133

Group type: COMPARATOR
Intervention: Comparison non-dietary behaviour
Number of subjects: 133
Study: 20921291

Group type: EXPERIMENTAL
Intervention: Calcitriol with lanthanum carbonate (3000 mg/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Calcitriol with sevelamer carbonate (7200 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Calcitriol alone
Number of subjects: 41
Study: 18850485

Group type: EXPERIMENTAL
Intervention: CABG plus mitral valve correction
Number of subjects: 550

Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 550
Study: 16720937

Group type: EXPERIMENTAL
Intervention: Endurance exercises for dorsiflexors (4 sets of 10 isometric contractions at 60% of MVC, 3X/week for 8 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Endurance exercises for dorsiflexors
Number of subjects: 10
Study: 15127672

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics as recommended by National Institute for Clinical Excellence guidelines
Number of subjects: 0
Study: 11744561

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 614
Study: 9403370

Group type: EXPERIMENTAL
Intervention: Teaching mental state understanding tasks to children with autism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8465360

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily
Number of subjects: 1473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1473
Study: 3898818

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at night (hs)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily (bid)
Number of subjects: 143
Study: 30387869

Group type: EXPERIMENTAL
Intervention: Single-implant mandibular overdenture (SIMO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional complete denture (CD)
Number of subjects: 34
Study: 29468383

Group type: EXPERIMENTAL
Intervention: Oral levocarnitine solution (50-100 mg/kg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional therapy (oral hydrochlorothiazide, enalapril, spironolactone; digoxin for NYHA grade IV; dopamine and dobutamine for intractable heart failure; metoprolol when cardiac function restored to NYHA grade II-III)
Number of subjects: 29
Study: 26751937

Group type: EXPERIMENTAL
Intervention: Nitrate (NIT) supplementation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NIT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 20
Study: 24111854

Group type: EXPERIMENTAL
Intervention: 3D animation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (narration and drawing)
Number of subjects: 68
Study: 22331280

Group type: EXPERIMENTAL
Intervention: Experimental muscle pain (induced by intramuscular injections of hypertonic (6%) saline)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (isotonic (0.9%) saline injections)
Number of subjects: 15
Study: 20565454

Group type: EXPERIMENTAL
Intervention: IK-1001 (Na2S) 0.005-0.20 mg kg(-1), i.v., infused over 1 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Na2S (sodium sulphide)
Number of subjects: 0
Study: 17077114

Group type: EXPERIMENTAL
Intervention: Subtenon injection of triamcinolone acetonide (TA) before laser grid pattern photocoagulation (G‐PC)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Laser grid pattern photocoagulation (G‐PC) without TA injection
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Subtenon injection of triamcinolone acetonide (TA) before G‐PC
Number of subjects: 37
Study: 15995772

Group type: EXPERIMENTAL
Intervention: Periocline administered subgingivally at baseline and weeks 1 to 4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no drug administered)
Number of subjects: 0
Study: 11955734

Group type: EXPERIMENTAL
Intervention: Combined radiotherapy and adjuvant chemotherapy (9 weekly cycles of 24-h infusional chemotherapy: 20 mg/m² cisplatin, 2,200 mg/m² 5-fluorouracil, and 120 mg/m² leucovorin) after RT
Number of subjects: 154

Group type: COMPARATOR
Intervention: Radiotherapy alone (35-40 fractions, 1.8-2.0 Gy/fraction/day, 5 days/week, total dose 70-72 Gy)
Number of subjects: 154
Study: 9434653

Group type: EXPERIMENTAL
Intervention: Practice guidelines
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study: 8568015

Group type: COMPARATOR
Intervention: Nefazodone single daily doses (5-500 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nefazodone multiple daily doses (5 mg or 10 mg 3 times a day to a maximum of 500 mg 3 times a day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nefazodone maximum tolerated level (up to 1350 mg total daily dose)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 2564834

Group type: EXPERIMENTAL
Intervention: Somatostatin (100 micrograms/h after a 250 microgram bolus for the first two days)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 97474

Group type: EXPERIMENTAL
Intervention: Monthly interviews
Number of subjects: 691

Group type: COMPARATOR
Intervention: Bimonthly interviews
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: In-person contact
Number of subjects: 691

Group type: COMPARATOR
Intervention: Telephone contact
Number of subjects: 691
Study: 31823379

Group type: EXPERIMENTAL
Intervention: Triad intervention with an additional TD peer added to the existing dyad, delivered over four clinic sessions by a trained occupational therapist.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Triad intervention with an additional TD peer added to the existing dyad.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dyad intervention as part of a randomised control trial investigation of the PLF.
Number of subjects: 15
Study: 31106851

Group type: EXPERIMENTAL
Intervention: DIFFMASK score (0 to 18 points)
Number of subjects: 46804
Study: 27838195

Group type: EXPERIMENTAL
Intervention: Pictorial image displays (Electronic Whiteboard - EWB) added to textual histories
Number of subjects: 0

Group type: COMPARATOR
Intervention: Textual information alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pictorial image displays (EWB)
Number of subjects: 0
Study: 24990176

Group type: EXPERIMENTAL
Intervention: Educational and behavioral intervention (EBI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 25
Study: 23444007

Group type: EXPERIMENTAL
Intervention: Industry-sponsored gifts
Number of subjects: 2350

Group type: EXPERIMENTAL
Intervention: Meals outside the hospital
Number of subjects: 2350

Group type: EXPERIMENTAL
Intervention: Free drug samples
Number of subjects: 2350

Group type: EXPERIMENTAL
Intervention: Perception of bias from industry interactions
Number of subjects: 2350

Group type: COMPARATOR
Intervention: NIH funding levels
Number of subjects: 2350

Group type: COMPARATOR
Intervention: Strength of institutional conflict of interest policies
Number of subjects: 2350
Study: 21291440

Group type: EXPERIMENTAL
Intervention: Parenting-focused preventive intervention
Number of subjects: 240
Study: 19267194

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 195
Study: 16778712

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg/d for 11 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg single oral dose)
Number of subjects: 12
Study: 15513547

Group type: EXPERIMENTAL
Intervention: VR implantation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Real surgery
Number of subjects: 39
Study: 10675059

Group type: EXPERIMENTAL
Intervention: Hyperoxic gas mixture (inspired oxygen fraction = 40%)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normoxic gas mixture
Number of subjects: 17
Study: 9264477

Group type: EXPERIMENTAL
Intervention: 10-week physical training
Number of subjects: 140
Study: 12959287

Group type: EXPERIMENTAL
Intervention: Tablet (155 mg rac‐hydroxychloroquine)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral solution (155 mg rac‐hydroxychloroquine)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fasted subjects (previously reported)
Number of subjects: 9
Study: 3040923

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (CAV and VP-16/cisplatin for six cycles)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sequential chemotherapy (three cycles of CAV followed by three of VP-16/cisplatin)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 300
Study: 30566245

Group type: EXPERIMENTAL
Intervention: Elective sigmoid resection
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 106
Study: 29463769

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (facilitated, group‐based educational discussion on mindful hand hygiene)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (no mindfulness intervention)
Number of subjects: 4
Study: 26525188

Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 25298043

Group type: EXPERIMENTAL
Intervention: Information regarding the trial; Enrollment process; Community involvement; Explanation of trial procedures and risks/benefits
Number of subjects: 300
Study: 22500385

Group type: EXPERIMENTAL
Intervention: Jinhuang Yidan Granule (JYD)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no Chinese medicine)
Number of subjects: 66
Study: 20602004

Group type: EXPERIMENTAL
Intervention: Moderately painful intracutaneous electrical stimuli
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 36
Study: 17591031

Group type: COMPARATOR
Intervention: d4T40 arm (stavudine 40 mg twice daily)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: d4T30 arm (stavudine 30 mg twice daily)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: TDF arm (switch to tenofovir)
Number of subjects: 58

Group type: COMPARATOR
Intervention: d4T40 arm
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: d4T30 arm
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: TDF arm
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58
Study: 15546225

Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 271

Group type: COMPARATOR
Intervention: Nutrition education
Number of subjects: 271
Study: 11503006

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Triazolam alone
Number of subjects: 30
Study: 9403400

Group type: EXPERIMENTAL
Intervention: Intervention service package
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1800